Matt Hoffman

The professor emeritus of psychiatry at the University of Pennsylvania’s Perelman School of Medicine discussed the imperative need for physicians to recognize tardive dyskinesia.

The assistant professor of neurology at Weill Cornell Medicine shared the findings from a recent study that suggested a heightened risk of stroke may linger up to 3 months after myocardial infarction.

Could big data, combined with a biomarker, provide beneficial information for physicians treating multiple sclerosis?

The professor emeritus of psychiatry at the University of Pennsylvania’s Perelman School of Medicine spoke about the condition and the available therapies, as well as some of the needs that remain unmet.

The associate professor of neurology and neuroscience at Weill Cornell Medicine spoke about the history of cell therapies for Parkinson disease and how it’s informing current work.

Cognitive complaints remain a major issue for patients with epilepsy, leading the epileptologist at the University of Pennsylvania to share her insight into addressing them.

The president of the ANA offered his perspective on these novel genetic therapies, as well as other a few other areas of interest.

The professor of psychiatry and neuroscience at the Icahn School of Medicine at Mount Sinai spoke about new study findings that suggest antidiabetic therapy could reduce Alzheimer genetic expression.

This is the first oral film formulation of clobazam approved, highlighting the challenge of medication administration in patients with LGS, who often struggle due to physical, behavioral, or cognitive impacts.

Although treatment needs to be assessed in a larger trial, it also showed improvements in 2 measurements of functional ability.

The compromised microvascular and insulin receptor signaling pathways seen in Alzheimer disease have been shown to be reduced or normalized by exposure to antidiabetic therapies.

The medical director of clinical development at Biogen spoke about the current use of the biomarker and the steps being taken clinically validate it.

The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University provided insight on the potential effect cladribine could have on multiple sclerosis.

In its second phase 2 trial, the therapy, also known as AMO-02, resulted in improvements in cognitive function, fatigue, and neuromuscular symptoms.

The president of the American Headache Society shared her thoughts on how preventive medicines can alter migraine treatment for the better.

Despite the explosion of preventive medications for migraine, a large need for acute care remains.

With many advancements in treatments occurring in recent years, the president of the American Headache Society urged for further research to continue to light the way.

As well as showing a positive impact on patient daily living and cognitive decline, data also confirmed SIGMAR1 and COMT as biomarkers of response to the therapy.

The authors suggested that the detection and tracking of seizure cycles on a patient-specific basis should be standard in epilepsy management practices.

Allergan is planning a 2019 NDA submission to the FDA for its agent, ubrogepant, based on a pair of new trials.

Within the defined amyloid-tau-neurodegeneration framework of Alzheimer disease, the investigational agent has displayed a hopeful effect on all 3 pieces.

Since the inception of the idea more than 3 decades ago and its initial development 20 years later, Sarepta Therapeutics’ micro-dystrophin gene therapy has now made its way to human trials.

The medical director of the UCSF Multiple Sclerosis Center provided some insight into the development of therapies for the purpose of remyelination.

The gene therapy is also being assessed for long-term safety data, as well as an additional delivery method.

Patients under the age of 65 were not shown to derive benefit from DBS, but researchers noted that this doesn’t mean it is not helpful for older patients.

With more than a dozen available therapies, disease-modification in multiple sclerosis is entering a new era of development.

Results suggested that for every 1% of brain volume lost, a 51.7% increase in risk of clinically definite MS conversion was observed.

The next important area of therapeutic development in MS appears to be in disease damage repair.

The monoclonal antibody has shown continued success up to 8 years in clinical trials.

This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.